Eli Lilly Takes 19.9% Stake In TRex Bio With 5.48M Shares, Investing $12.3M In IPO
The Reporting Person beneficially owns an aggregate of 5,480,872 shares of Common Stock of the Issuer, consisting of (a) 2,510,411 shares of Common Stock that were issued to the Reporting Person upon conversion of
Eli Lilly, a big medicine company, bought a large piece of TRex Bio. This shows Eli Lilly believes in TRex and wants to help it grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.